MMR Global and Claydata enter into licensing agreement
Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.
Aurobindo sued by Pfizer over skin antibiotic
Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.
Actavis completes $1.1bn Furiex acquisition
Actavis’s newly-acquired subsidiary Forest Laboratories has bought drug development company Furiex Pharmaceuticals for $1.1 billion.
Johnson & Johnson IP chief lined up for USPTO role
The head of IP at a major pharmaceutical company is set to be named as the next director of the US Patent and Trademark Office, reports have claimed.
Genentech adds to breast cancer pipeline with Seragon buyout
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion.
Bingham boosts life sciences practice
Patent counselling specialist Mark Hayman has joined Bingham McCutchen LLP’s Boston office as a partner.
Forest sues to stop Aurobindo’s generic Namenda
New York-headquartered Forest Laboratories has filed suit against Indian company Aurobindo Pharma to protect Namenda, a treatment for moderate to severe Alzheimer’s disease.
BIO 2014: UAE judges may not yet be ready to deal with biotech cases
IP legislation in the United Arab Emirates is among the strongest in the region but the courts have had so few issues to handle that the country’s lawyers and judges may not yet be well equipped to deal with biotech cases.
BIO 2014: Post-Myriad patent rejections 'incredibly case-specific'
Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday.
BIO 2014: Open innovation a threat to research institutes
An increasing trend among scientists to want to put their new ideas into the public domain to be shared for the benefit of all is putting research bodies that rely on partnerships with industry for a substantial proportion of their income at risk, according to Jean Derégnaucourt, executive vice-president for business development at the Institut Pasteur in Paris.
